Finerenone for IgA Nephropathy After Renin‐Angiotensin System Inhibitors Discontinuation: A Multicentre Retrospective Cohort Study
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71225 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Fang Zeng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme Inhibitors, Glomerulonephritis, IGA. Die Arbeit nennt 32 Literaturangaben. Gefördert von: "Thousand Talents Plan" project of introducing and training high-level talents of innovation and entrepreneurship in Jiangxi Province, Key Clinical Research Project of the Second Affiliated Hospital of Nanchang University, Key Project of Jiangxi Provincial Nature Science Foundation.
Abstract (Originalsprache)
Background
Finerenone has emerged as a promising therapeutic agent for IgA nephropathy (IgAN). The role of finerenone in IgAN patients who have discontinued renin‐angiotensin system inhibitor (RASi) therapy remains poorly defined.
Methods
This retrospective, multicentre cohort study enrolled patients with primary IgAN who received finerenone and/or RASi treatment. Participants were categorised into three groups: the finerenone plus RASi, finerenone (after RASi discontinuation) and RASi groups. All participants had a baseline estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m 2 and urinary total protein (UTP) ≥ 0.5 g/day. The primary outcomes included the percentage change in UTP from baseline and the rate of significant response (defined as ≥ 50% reduction in UTP and < 20% increase in serum creatinine).
Results
Following 1:1:1 propensity score matching, a total of 258 patients were analysed, with 86 in each group. At 12 months, UTP decreased by 32.24% in the finerenone group and 34.35% in the RASi group ( p = 0.220). The finerenone plus RASi group achieved a significantly greater reduction of 54.43% compared with either monotherapy group (both p < 0.01). Kaplan–Meier analysis confirmed that the finerenone plus RASi group achieved superior significant response rates compared with either monotherapy group (both log‐rank p = 0.001). No significant difference was observed between the RASi and finerenone groups (log‐rank p = 0.856). Although the finerenone plus RASi group exhibited a numerically steeper total eGFR decline (−1.48 vs. −0.44 vs. −0.52 mL/min/1.73 m 2 /year) and a greater increase in the chronic eGFR slope (0.66 vs. 0.37 vs. 0.49 mL/min/1.73 m 2 /year), neither difference reached statistical significance compared with the finerenone or RASi groups. The incidence of adverse events was comparable across all three groups.
Conclusion
Finerenone achieved short‐term proteinuria reductions in RASi discontinued IgAN patients similar to those achieved with RASi monotherapy. Finerenone combined with RASi enhanced antiproteinuric efficacy while maintaining safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
- Department of Nephrology, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University, Ganzhou, China.
- Department of Health Management Center, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
- Department of Health Management Center, Jiangxi Provincial People's Hospital, Nanchang, China.
- Department of Nephrology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
- Department of Nephrology, Yingtan 184 Hospital, Yingtan, China.
ORCID-Profile: Yebei Li, Xiaoli Wen, Gaosi Xu
Förderung
- "Thousand Talents Plan" project of introducing and training high-level talents of innovation and entrepreneurship in Jiangxi Province
- Key Clinical Research Project of the Second Affiliated Hospital of Nanchang University
- Key Project of Jiangxi Provincial Nature Science Foundation
Zitieren
APA
Zeng, F., Li, X., Yang, Y., Zhang, R., Li, Y., Ren, D., Wen, X., Yan, W., Wang, Y., Xie, X., Liu, D., & Xu, G. (2026). Finerenone for IgA Nephropathy After Renin‐Angiotensin System Inhibitors Discontinuation: A Multicentre Retrospective Cohort Study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71225
Vancouver
Zeng F, Li X, Yang Y, Zhang R, Li Y, Ren D, et al. Finerenone for IgA Nephropathy After Renin‐Angiotensin System Inhibitors Discontinuation: A Multicentre Retrospective Cohort Study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71225
BibTeX
@article{Zeng2026,
author = {Zeng, Fang and Li, Xiang and Yang, Yang and Zhang, Ran and Li, Yebei and Ren, Daijin and Wen, Xiaoli and Yan, Wenjun and Wang, Yu and Xie, Xiaojie and Liu, Dehui and Xu, Gaosi},
title = {Finerenone for IgA Nephropathy After Renin‐Angiotensin System Inhibitors Discontinuation: A Multicentre Retrospective Cohort Study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71225}
}
EUVIMED